JAMP GATIFLOXACIN DIN 02533235
Health Canada record
| Active ingredient(s) | GATIFLOXACIN 0.3 % |
|---|---|
| Dosage form | Solution |
| Route | Ophthalmic |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | S01AE06 GATIFLOXACIN |
| Original market date | 05-Dec-2024 |
| Current status date | 05-Dec-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing GATIFLOXACIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02257270 | ZYMAR | ABBVIE CORPORATION | Solution | GATIFLOXACIN 0.3 % | Marketed |
| 02271052 | NOVO-GATIFLOXACIN | NOVOPHARM LIMITED | Tablet | GATIFLOXACIN 400 MG | Cancelled Pre Market |
| 02408481 | SANDOZ GATIFLOXACIN | SANDOZ CANADA INCORPORATED | Solution | GATIFLOXACIN 3 MG | Cancelled Pre Market |
| 02243182 | TEQUIN | BRISTOL-MYERS SQUIBB CANADA | Tablet | GATIFLOXACIN 400 MG | Cancelled Post Market |
| 02243181 | TEQUIN | BRISTOL-MYERS SQUIBB CANADA | Tablet | GATIFLOXACIN 200 MG | Cancelled Post Market |
| 02243184 | TEQUIN IV | BRISTOL-MYERS SQUIBB CANADA | Liquid | GATIFLOXACIN 10 MG | Cancelled Post Market |
| 02243183 | TEQUIN IV | BRISTOL-MYERS SQUIBB CANADA | Solution | GATIFLOXACIN 2 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 29786 | 2022-12-29 | Abbreviated New Drug Submission (ANDS) |
International API supply for GATIFLOXACIN
7 active FDA Drug Master Files.
Request a quote for JAMP GATIFLOXACIN